Generics Bulletin is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Aidan Fry

With over 20 years of experience of reporting on the global pharmaceutical industry, Aidan focuses in his role as editor of Generics bulletin particularly on commercial, regulatory and legal issues affecting the generic, biosimilar, value-added and OTC medicines industries. This includes in-depth analyses of corporate strategy, legislative changes, legal precedents and product perspectives. He regularly interviews leading industry executives and moderates prestigious events. Aidan also oversees the Global Generics & Biosimilars Awards. Aidan speaks fluent German and has a particular affection for maps.
Advertisement
Set Alert for Articles By Aidan Fry

Latest From Aidan Fry

Sandoz Phases US Epinephrine Entry

Sandoz will first focus on the US institutional channel on which it is increasingly concentrating its attention as it rolls out its alternative to Mylan’s EpiPen epinephrine auto-injector.
Value-Added Medicines Launches

Wockhardt Wins Review Of Ban On Indian Combination

Evidence put forward by manufacturers to support fixed-dose combinations must be considered by an advisory committee to India’s government, the Delhi High Court has ordered in a verdict favouring Wockhardt.
India Regulation

Court Clears Teva After At-Risk Budesonide Entry

Teva has escaped potential damages from its ‘at risk’ US launch of budesonide extended-release tablets after a US Court of Appeals upheld a previous non-infringement ruling.
Intellectual Property Gastrointestinal

Sandoz’ Hexal Avoids German Fulvestrant Use Patent

Any prescribing of Hexal’s generic fulvestrant in Germany for uses covered by AstraZeneca’s patent would be so minimal as to be irrelevant, a regional court of appeals has ruled.
Germany Cancer

Amerigen’s Attempt To Force Fesoterodine Entry Fails

Amerigen Pharmaceuticals has failed to convince a US Court of Appeals to remove a patent and thus allow the company to launch a generic of Pfizer’s Toviaz (fesoterodine) this year.
Intellectual Property Gynecology & Urology

Alvotech Advances Partnerships To Take Pipeline Global

By the middle of this year, biosimilars developer Alvotech plans to have strategic alliances in place with a handful of regional partners to commercialize its pipeline of seven biosimilar monoclonal antibodies.
Biosimilars Business Strategies
See All
Advertisement
UsernamePublicRestriction

Register